Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 5/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | SYK | P43405 | 2/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6619566 | 0.89 | NAAA (0.40) | NAAASLC6A5EGFRSYKALOX5 | |
| SCHEMBL6616584 | 0.79 | EGLN1 (0.40) | NAAASYK | |
| SCHEMBL12608923 | 0.78 | NAAA (0.62) | NAAAEGFRSYKALOX5PTGS2 | |
| SCHEMBL6186618 | 0.77 | CA12 (0.46) | EGFRALOX5PTGS2 | |
| SCHEMBL6614575 | 0.71 | ALDH1A1 (0.39) | — | |
| SCHEMBL4809608 | 0.69 | ALDH1A1 (0.36) | — | |
| SCHEMBL12041029 | 0.66 | NAAA (0.60) | NAAAALOX5 | |
| SCHEMBL6264342 | 0.66 | HPGD (0.49) | SLC6A5 | |
| SCHEMBL17289507 | 0.65 | HDAC1 (0.50) | — | |
| SCHEMBL17774845 | 0.65 | ALOX5 (0.50) | NAAAEGFRSYKALOX5PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1521742-A1 | DIPHENYLAZETIDINONE DERIVATIVES FOR TREATING DISORDERS OF THE LIPID METABOLISM | AstraZeneca AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004005247-A1 | DIPHENYLAZETIDINONE DERIVATIVES FOR TREATING DISORDERS OF THE LIPID METABOLISM | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |